miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia

Pharmacological inhibition of MDM2/4, which activates the critical tumor suppressor p53, has been gaining increasing interest as a strategy for the treatment of acute myeloid leukemia (AML). While clinical trials of MDM2 inhibitors have shown promise, responses have been confined to largely molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Thi Thanh, Stölzel, Friedrich, Wang, Kristy W., Röllig, Christoph, Tursky, Melinda L., Molloy, Timothy J., Ma, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257503/
https://www.ncbi.nlm.nih.gov/pubmed/33262524
http://dx.doi.org/10.1038/s41375-020-01095-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257503/
https://www.ncbi.nlm.nih.gov/pubmed/33262524
http://dx.doi.org/10.1038/s41375-020-01095-z

Ejemplares similares